Author:
Hirata Koki,Matsumoto Kunichika,Onishi Ryo,Hasegawa Tomonori
Abstract
PurposeThe purpose of this article is to clarify the social burden of Japan’s three major diseases including Long-term Care (LTC) burden.Design/methodology/approachA modification of the Cost of Illness (COI)—the Comprehensive-COI (C-COI) was utilized to estimate three major diseases: cancer, heart disease, and cerebrovascular diseases (CVD). The C-COI consists of five parts: medical direct cost, morbidity cost, mortality cost, formal LTC cost and informal LTC cost. The latter was calculated by two approaches: opportunity cost approach (OC) and replacement approach (RA), which assumed that informal caregivers were substituted by paid caregivers.FindingsThe C-COI of cancer, heart disease and CVD in 2017 amounted to 10.5 trillion JPY, 5.2 trillion JPY, and 6.7 trillion JPY, respectively (110 JPY= 1 US$). The mortality cost was preponderant for cancer (61 percent) and heart disease (47.9 percent); while the informal LTC cost was preponderant for CVD (27.5 percent). The informal LTC cost of the CVD in OC amounted to 1.8 trillion JPY; while the RA amounted to 3.0 trillion JPY.Social implicationsThe LTC burden accounted for a significant proportion of the social burden of chronic diseases. The informal care was maintained by unsustainable structures such as the elderly providing care for the elderly. This result can affect health policy decisions.Originality/valueThe C-COI is more appropriate for estimating the social burden of chronic diseases including the LTC burden and can be calculated using governmental statistics.
Subject
General Medicine,General Arts and Humanities
Reference52 articles.
1. Cabinet Office (2018), “Monetary valuation of unpaid work”, available at: https://www.esri.cao.go.jp/jp/sna/sonota/satellite/roudou/roudou_top.html (accessed 29 January 2021) (in Japanese).
2. Estimating the long-term costs of ischemic and hemorrhagic stroke for Australia: new evidence derived from the North East Melbourne Stroke Incidence Study (NEMESIS);Stroke,2009
3. Are cost of injury studies useful?;Injury Prevention,2000
4. The cost of oncology drugs: a pharmacy perspective (Part I);Federal Practitioner,2016
5. Cost of Illness in subarachnoid hemorrhage: a German longitudinal study;Stroke,2010
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献